Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention
暂无分享,去创建一个
Rudolf T Hoogenveen | Talitha L Feenstra | Caroline A Baan | R. Hoogenveen | C. Baan | T. Feenstra | G. Kommer | Pieter M van Baal | Monique O Jacobs-van der Bruggen | Geert-Jan Kommer | P. V. van Baal
[1] J. Richardson,et al. Cost-Effectiveness of the Primary Prevention of Non-Insulin Dependent Diabetes Mellitus , 1997 .
[2] O. Franco,et al. Cost effectiveness of statins in coronary heart disease , 2005, Journal of Epidemiology and Community Health.
[3] W. Groot,et al. Costs of the 'Hartslag Limburg' community heart health intervention , 2006, BMC public health.
[4] M K Campbell,et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.
[5] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[6] Rudolf T Hoogenveen,et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation , 2008, Cost effectiveness and resource allocation : C/E.
[7] Rudolf T Hoogenveen,et al. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. , 2010, Mathematical medicine and biology : a journal of the IMA.
[8] E. Feskens,et al. Lifestyle intervention according to general recommendations improves glucose tolerance. , 2003, Obesity research.
[9] Ping Zhang,et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Reiner Leidl,et al. A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries , 2012, PharmacoEconomics.
[11] S. Ward,et al. A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.
[12] R. Hoogenveen,et al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] N. Chaturvedi. The burden of diabetes and its complications: trends and implications for intervention. , 2007, Diabetes research and clinical practice.
[14] P. Engelfriet,et al. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[15] G. Bray,et al. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.
[16] Hendriek C Boshuizen,et al. Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. , 2006, American journal of epidemiology.
[17] M A Koopmanschap,et al. Resource consumption and costs in Dutch patients with Type 2 diabetes mellitus. Results from 29 general practices , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[18] A. Gafni,et al. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.
[19] C. Murray,et al. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. , 1994, Bulletin of the World Health Organization.
[20] Jantine Schuit,et al. The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. , 2008, Preventive medicine.
[21] P. Engelfriet,et al. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[22] D. Greenwood,et al. Structured patient education: the Diabetes X‐PERT Programme makes a difference , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[23] Anke Richter,et al. Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[24] Neil Chapman,et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.
[25] N. Graves,et al. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol , 2007, Chronic illness.
[26] P. Clarke,et al. The economic analyses of the UK prospective diabetes study , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[27] R. Hutubessy,et al. Lifetime health effects and costs of diabetes treatment. , 2003, The Netherlands journal of medicine.
[28] J. Bottomley,et al. Pharmaco-economic issues for diabetes therapy. , 2007, Best practice & research. Clinical endocrinology & metabolism.
[29] Amiram Gafni,et al. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. , 2003, Social science & medicine.
[30] J. Shearer,et al. Cost effectiveness analysis of smoking cessation interventions , 2006, Australian and New Zealand journal of public health.
[31] P. van Baal,et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. , 2007, Health economics.
[32] C. Baan,et al. Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus , 2012, PharmacoEconomics.
[33] T. Marshall,et al. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study , 2002, BMJ : British Medical Journal.
[34] S. Golder,et al. Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.
[35] R. Koopman,et al. Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way , 2006, Diabetologia.
[36] E. Feskens,et al. Cost-Effectiveness of Lifestyle Modification in Diabetic Patients , 2009, Diabetes Care.
[37] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[38] R. Hoogenveen,et al. Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk , 2007, Diabetes Care.